GlassScriptPhysician profile
Afshan A Khan
NPI 1568621233
$1,266.45
in general payments reported to CMS, 2019-2025
18 companies · $110 in 2025
The $110 reported for 2025 was less than what a typical Psychiatry provider received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $58.60 · 2020: $87.22 · 2021: $161 · 2022: $451 · 2023: $317 · 2024: $81.68 · 2025: $110.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $508.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $508.47 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $234.98 | 2020-2023 | Trintellix |
| Supernus Pharmaceuticals, INC. | $172.50 | 2021-2025 | Qelbree, Qelbree |
| Otsuka America Pharmaceutical, INC. | $166.84 | 2022-2023 | Rexulti |
| Corium, LLC | $147.96 | 2022-2024 | Azstarys |
| Abbvie INC. | $128.09 | 2022 | |
| Ironshore Pharmaceuticals INC. | $89.03 | 2019-2023 | Jornay Pm |
| Lundbeck LLC | $81.15 | 2022-2024 | Rexulti |
| Noven Therapeutics, LLC | $56.03 | 2023 | Xelstrym, Secuado |
| Tempus Ai, INC | $34.03 | 2025 | Tempus Pixel |
| Axsome Therapeutics, INC. | $23.15 | 2023 | Auvelity |
| Janssen Pharmaceuticals, INC | $22.57 | 2024 | Spravato |
| Novo Nordisk INC | $19.75 | 2022 | |
| Neurocrine Biosciences, INC. | $19.40 | 2019 | |
| Shire North American Group INC | $15.14 | 2019 | |
| Brainsway USA INC | $14.94 | 2022 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Owp Pharmaceuticals, INC. | $13.80 | 2021 | |
| Adlon Therapeutics L.P. | $13.60 | 2020 | |
| Vertical Pharmaceuticals, LLC | $13.49 | 2024 | Relexxii |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Afshan Khan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.